Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience
- 1 February 2016
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 42 (2) , 267-271
Abstract
Splanchnic vein thrombosis (SVT) is an uncommon form of venous thrombosis. Management can be challenging due to underlying conditions, increased bleeding risk, and lack of evidence from clinical trials. We sought to characterize the presentation and management of patients with SVT at a large tertiary hospital. A total of 43 patients’ electronic medical records were reviewed. Median age at diagnosis was 43 (18–71). Sixteen patients had isolated portal vein thrombosis (37.2 %), and 16 (37.2 %) had thrombosis involving multiple splanchnic veins. Abdominal pain was the most common clinical presentation (67.4 %). Thrombophilia was present in 18 patients (41.9 %), nine had underlying liver disease (20.9 %) and seven had inflammatory bowel disease (16.3 %). Thirty-nine (90.7 %) patients were treated with anticoagulation, and 11(25.6 %) of these patients underwent interventional procedures. Thirty (69.8 %) patients remained on indefinite anticoagulation. Results of follow-up imaging at least 1 month after diagnosis were available for 29 patients; imaging showed chronic, stable thrombosis in 14 patients (48.3 %), resolution of thrombosis in 13 patients (44.8 %) and asymptomatic progression in two patients (6.9 %). Recurrent thrombosis occurred in four patients (9.3 %). Major bleeding occurred in eight patients who received anticoagulation (18.6 %), including fatal subdural hematoma in one patient. In this cohort of patients managed by hematologists and gastroenterologists, the majority of patients were treated with anticoagulation. Interventional procedures were higher than in previously reported series. Our study strongly supports the interdisciplinary management of splanchnic venous thrombosis.Keywords
This publication has 19 references indexed in Scilit:
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- Andexanet Alfa for the Reversal of Factor Xa Inhibitor ActivityNew England Journal of Medicine, 2015
- Idarucizumab for Dabigatran ReversalNew England Journal of Medicine, 2015
- Treatment of Acute Portal Vein Thrombosis by Nontraditional AnticoagulationHepatology, 2014
- Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International RegistrySeminars in Thrombosis and Hemostasis, 2013
- Splanchnic vein thrombosis in myeloproliferative neoplasmsBritish Journal of Haematology, 2013
- Clinical approach to splanchnic vein thrombosis: Risk factors and treatmentThrombosis Research, 2012
- The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosisJournal of Thrombosis and Thrombolysis, 2012
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005